Float Short %

5.19

Margin Of Safety %

Put/Call OI Ratio

1.82

EPS Next Q Diff

0.04

EPS Last/This Y

-2.13

EPS This/Next Y

0.13

Price

10.06

Target Price

19.24

Analyst Recom

Performance Q

-2.52

Upside

-338.4%

Beta

1.34

Ticker: IMTX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	IMTX	9.9	0.68	70.00	712
2026-01-26	IMTX	9.71	1.00	0.00	854
2026-01-27	IMTX	9.99	1.00	0.00	854
2026-01-28	IMTX	9.7	0.98	0.00	861
2026-01-29	IMTX	9.35	0.97	32.50	865
2026-01-30	IMTX	9.53	1.12	999.99	932
2026-02-02	IMTX	10	1.39	0.00	1052
2026-02-03	IMTX	9.97	1.39	0.00	1053
2026-02-04	IMTX	9.36	1.38	55.00	1056
2026-02-05	IMTX	8.56	1.50	999.99	1112
2026-02-06	IMTX	9.56	1.50	999.99	1112
2026-02-09	IMTX	10.3	1.85	0.00	1268
2026-02-10	IMTX	9.95	1.83	0.00	1272
2026-02-11	IMTX	10.28	1.83	0.00	1272
2026-02-12	IMTX	9.93	1.79	999.99	1282
2026-02-13	IMTX	9.86	1.88	999.99	1322
2026-02-17	IMTX	9.89	1.88	0.00	1323
2026-02-18	IMTX	9.95	1.88	0.10	1324
2026-02-20	IMTX	10.09	1.82	145.00	1339
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	IMTX	9.90	-204.8	-	-1.97
2026-01-26	IMTX	9.71	-204.8	-	-1.97
2026-01-27	IMTX	9.97	-204.8	-	-1.97
2026-01-28	IMTX	9.70	-204.8	-	-1.97
2026-01-29	IMTX	9.36	-204.8	-	-1.97
2026-01-30	IMTX	9.54	-204.8	-	-1.97
2026-02-02	IMTX	10.00	-204.8	-	-1.97
2026-02-03	IMTX	9.97	-204.8	-	-1.97
2026-02-04	IMTX	9.37	-204.8	-	-1.97
2026-02-05	IMTX	8.56	-204.8	-	-1.97
2026-02-06	IMTX	9.60	-204.8	-	-1.97
2026-02-09	IMTX	10.30	-204.8	-	-1.97
2026-02-10	IMTX	9.96	-204.8	-	-1.97
2026-02-11	IMTX	10.27	-204.8	-	-1.97
2026-02-12	IMTX	9.92	-204.8	-	-1.97
2026-02-13	IMTX	9.82	-204.8	-	-1.97
2026-02-17	IMTX	9.93	-204.8	-	-1.97
2026-02-18	IMTX	9.97	-204.8	-	-1.97
2026-02-19	IMTX	10.30	-204.8	-	-1.97
2026-02-20	IMTX	10.06	-204.8	-	-1.97
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	IMTX	0.00	-4.98	46.97
2026-01-26	IMTX	0.00	-5.10	5.04
2026-01-27	IMTX	0.00	-5.10	5.04
2026-01-28	IMTX	0.00	-5.10	4.95
2026-01-29	IMTX	0.00	-5.10	4.95
2026-01-30	IMTX	0.00	-5.10	4.95
2026-02-02	IMTX	0.00	-5.10	4.95
2026-02-03	IMTX	0.00	-5.10	4.95
2026-02-04	IMTX	0.00	-5.10	4.95
2026-02-05	IMTX	0.00	-5.10	4.95
2026-02-06	IMTX	0.00	-5.10	4.95
2026-02-10	IMTX	0.00	-4.89	4.95
2026-02-11	IMTX	0.00	-4.89	5.13
2026-02-12	IMTX	0.00	-4.89	5.13
2026-02-13	IMTX	0.00	-4.89	5.13
2026-02-17	IMTX	0.00	-0.20	5.13
2026-02-18	IMTX	0.00	-0.20	5.13
2026-02-19	IMTX	0.00	-0.20	5.13
2026-02-20	IMTX	0.00	-0.20	5.19
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.49

Avg. EPS Est. Current Quarter

-0.47

Avg. EPS Est. Next Quarter

-0.45

Insider Transactions

Institutional Transactions

-0.2

Beta

1.34

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

45.4

Max Drawdown 5-Year %

-77.4

Target Price

19.24

P/E

Forward P/E

PEG

P/S

14.82

P/B

2.5

P/Free Cash Flow

EPS

-1.09

Average EPS Est. Cur. Y

-1.97

EPS Next Y. (Est.)

-1.84

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-146.05

Relative Volume

0.86

Return on Equity vs Sector %

-56.8

Return on Equity vs Industry %

-39.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.07

EBIT Estimation

Immatics N.V.

Sector: Healthcare

Industry: Biotechnology

Employees: 645

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

stock quote shares IMTX – Immatics N.V Stock Price stock today

news today IMTX – Immatics N.V stock forecast ,stock prediction 2023 2024 2025

marketwatch IMTX – Immatics N.V yahoo finance google finance

stock history IMTX – Immatics N.V invest stock market

stock prices IMTX premarket after hours

ticker IMTX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: IMTX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y